Orexo
12,88 SEK -4,45%Vær den første som følger denne virksomhed
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Omsætning
638,8 mio.
EBIT %
-17,14 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ORX
Daglig lav / høj pris
12,62 / 13,44
SEK
Markedsværdi
447,07 mio. SEK
Aktieomsætning
280,22 t SEK
Volumen
22 t
Seneste videoer
Finanskalender
Delårsrapport
24.10.2024
Årsrapport
06.02.2025
Delårsrapport
06.05.2025
Delårsrapport
16.07.2025
Delårsrapport
23.10.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Novo A/S | 27,8 % | 27,8 % |
Avanza Pension | 6,8 % | 6,8 % |
Arbejdsmarkedets Tillaegspension (ATP) | 5,1 % | 5,1 % |
Anders Walldov direct and indirect | 4,6 % | 4,6 % |
Swedbank Insurance | 2,8 % | 2,8 % |
Nordnet Pension Insurance | 1,7 % | 1,7 % |
Stefan Hansson | 1,3 % | 1,3 % |
Håkan Lejonkula | 1,2 % | 1,2 % |
Christer Nyström | 0,7 % | 0,7 % |
Eccenovo AB | 0,7 % | 0,7 % |
ViserAlle indholdstyper
Invitation to presentation of Orexo´s Q3 2024 Interim Report
Orexo's Nomination Committee for the Annual General Meeting 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools